Despite recent earnings growth, the company's P/E ratio is lower than the market, indicating shareholders may think the company has peaked. The company's three-year earnings trends aren't impacting its P/E as anticipated, hinting at potential unseen earnings threats.

Despite Baotou Dongbao Bio-Tech's slightly low ROE, the company's net income growth and inferred efficient management stand out. Although the ROE is lower, significant future earnings growth is anticipated given the high reinvestment rate.